{
    "clinical_study": {
        "@rank": "73673", 
        "arm_group": [
            {
                "arm_group_label": "MSJ-0011", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "urinary hCG", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, parallel-group, randomized, multicenter Phase III trial to compare\n      the efficacy and safety of a single 250 \u03bcg subcutaneous dose of MSJ-0011 to a single 5,000\n      IU intramuscular dose of urinary hCG in inducing ovulation in Japanese women diagnosed with\n      anovulation or oligo-ovulation.  Ovulation induction therapy will be undertaken with\n      follitropin alfa. The primary objective is to show that MSJ-0011 is non-inferior to urinary\n      hCG, as assessed by the ovulation rate."
        }, 
        "brief_title": "Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anovulation", 
            "Oligo-ovulation", 
            "Hypothalamic-pituitary Dysfunction", 
            "Polycystic Ovarian Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anovulation", 
                "Polycystic Ovary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Premenopausal women aged between 20 to 39 years inclusive and wishing to conceive.\n\n          -  BMI of 17.0 to 29.0 kg/m2 inclusive (value up to first decimal place).\n\n          -  No clinically significant abnormalities in serum TSH, DHEA-S, 17-OHP, PRL and FSH\n             levels in the early follicular phase.\n\n          -  Anovulation or oligo-ovulation.\n\n          -  Any one of the following: spontaneous menstruation (at least twice per year) or a\n             positive response to progestin as evidenced by menstruation.\n\n          -  Eligible for ovarian stimulation with gonadotropins (e.g. documented failure to\n             ovulate or achieve pregnancy with anti-estrogenic therapy such as clomiphene\n             citrate).\n\n          -  Male partner with normal semen analysis, as defined by WHO standards, within 12\n             months prior to date of informed consent.\n\n          -  Normal cervical smear results (PAP score \u2264 II) taken within 12 months prior to date\n             of informed consent; if not available a cervical smear will be performed as part of\n             screening.\n\n          -  Full comprehension of the trial and voluntary consent obtained in writing prior to\n             participation in this trial.\n\n        Exclusion Criteria:\n\n          -  Infertility involving gynecological factors other than anovulation or oligo-ovulation\n             secondary to hypothalamic-pituitary dysfunction (Grade 1 Amenorrhea, Oligomenorrhea\n             or Anovulatory Cycles) or PCOS, and for whom OI therapy is contraindicated.\n\n          -  Subjects with known surgical/histological diagnosis of endometriosis greater than\n             Stage II (American Fertility Society classification), or endometriosis requiring\n             treatment.\n\n          -  Infertility secondary to amenorrhea of uterine cause.\n\n          -  Infertility secondary to primary or premature ovarian failure.\n\n          -  Infertility secondary to known adrenal or thyroid dysfunction, or hyperprolactinemia.\n\n          -  Failure of ovulation in 2 or more consecutive previous cycles with any gonadotropins.\n\n          -  Subjects in whom pregnancy is contraindicated, e.g. malformations of sexual organs or\n             fibroid tumors of the uterus incompatible with pregnancy.\n\n          -  Extrauterine pregnancy in the previous 3 months.\n\n          -  History or presence of intracranial tumor (e.g. hypothalamic or pituitary tumor).\n\n          -  Presence of or suspected gonadotropin- or estrogen-dependent malignancy (e.g.\n             ovarian, uterine or mammary carcinoma).\n\n          -  Untreated endometrial hyperplasia.\n\n          -  Abnormal hemorrhage of the reproductive tract of unknown origin.\n\n          -  History of severe ovarian hyperstimulation syndrome (OHSS) (Classification of OHSS\n             Severity, Japan Reproductive/Endocrine Working Group).\n\n          -  Clinically significant systemic disease (e.g. insulin-dependent diabetes, epilepsy,\n             severe migraine, intermittent porphyria, hepatic, renal or cardiovascular disease,\n             severe corticosteroid-dependent asthma).\n\n          -  Participation in another clinical trial within 3 months prior to date of informed\n             consent or simultaneous participation in another clinical trial.\n\n          -  Gonadotropin treatment within 2 months prior to date of informed consent.\n\n          -  Legal incapacity or limited legal capacity."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "39 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "87", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653743", 
            "org_study_id": "EMR701173_002"
        }, 
        "intervention": [
            {
                "arm_group_label": "MSJ-0011", 
                "description": "MSJ-0011, single 250 \u03bcg subcutaneous dose, presented in a prefilled syringe", 
                "intervention_name": "MSJ-0011", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "urinary hCG", 
                "description": "Urinary hCG, single 5,000 IU intramuscular dose (freeze-dried formulation)", 
                "intervention_name": "urinary hCG", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Chorionic Gonadotropin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Japanese", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan"
                    }, 
                    "name": "Hanabusa Women's Central Fertility Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan"
                    }, 
                    "name": "Bashamichi Ladies Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan"
                    }, 
                    "name": "Sophia Ladies Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "Ivf Osaka Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "Ivf Namba Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan"
                    }, 
                    "name": "Department of Obstetrics and Gynecology, Saitama Medical University Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open-label, Parallel-group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 \u03bcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-ovulation Secondary to Hypothalamic-pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa", 
        "overall_contact": {
            "email": "yukito.kuwahara@merckgroup.com", 
            "last_name": "Yukito Kuwahara, Clinical Trial Leader", 
            "phone": "+81-3-6853-8511"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mid-luteal serum progesterone values will reflect the higher of the values taken during the visit on day 5-7 and the visit on day 8-10.  However, if clinical pregnancy is achieved, then this will be counted as successful ovulation regardless of the mid-luteal serum progesterone levels.", 
            "measure": "Title:  Percentage of Participants Who Ovulated, defined as mid-luteal serum progesterone levels of >= 5 ng/mL or a clinical pregnancy", 
            "safety_issue": "No", 
            "time_frame": "up to study day 10"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653743"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Mid-luteal serum progesterone values will reflect the higher of the values taken during the visit on day 5-7 and the visit on day 8-10.  However, if clinical pregnancy is achieved, then this will be counted as successful ovulation regardless of the mid-luteal serum progesterone levels.", 
                "measure": "Title:  Percentage of Participants Who Ovulated, defined as mid-luteal serum progesterone levels of >= 9.4 ng/mL or a clinical pregnancy", 
                "safety_issue": "No", 
                "time_frame": "up to study day 10"
            }, 
            {
                "description": "Endometrial thickness will be measured using transvaginal ultrasound", 
                "measure": "Mid-luteal Endometrial Thickness", 
                "safety_issue": "No", 
                "time_frame": "study days 5-7"
            }, 
            {
                "description": "Biochemical pregnancy is defined as a positive result to the serum \u03b2-hCG pregnancy", 
                "measure": "Percentage of Participants Who Had a Biochemical Pregnancy", 
                "safety_issue": "No", 
                "time_frame": "study days 15-20"
            }, 
            {
                "measure": "Percentage of Participants Who Had a Clinical Pregnancy", 
                "safety_issue": "No", 
                "time_frame": "study days 35-42"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Serono Co., Ltd., Japan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}